講演情報
[3-PB-2-05]【学術】Real-world outcomes of first-line atezolizumab plus bevacizumab and lenvatinib in hepatocellular carcinoma without prior locoregional therapy
Seung-Hun You1, Ah Young Lee2, Kwanjoo Lee3, Jungho Ahn4,5, Jun-young Seo3, *Wonsuk Shin1,6,7 (1. Medical Big Data Research Center、CHA University Bundang Medical Center、Seongnam、Republic of Korea、2. Digestive Disease Center、CHA University Gangnam Medical Center、Seoul、Republic of Korea、3. Digestive Disease Center、CHA University Bundang Medical Center、Seongnam、Republic of Korea、4. Department of Biophysics、Institute of Quantum Biophysics、Sungkyunkwan University、Suwon-si、Gyeonggi-do、Republic of Korea、5. Department of MetaBioHealth、Sungkyunkwan University、Suwon、Gyeonggi-do、Republic of Korea、6. Department of Physiology、School of Medicine、CHA University、Pocheon-si、Republic of Korea、7. Department of Clinical Pharmacology & Therapeutics、CHA University Bundang Medical Center、Seongnam、Republic of Korea)